82 related articles for article (PubMed ID: 1562559)
1. Role of cell growth factor (interleukin-2) and its receptors in carcinoma cervix patients.
Rani S; Vaidya MC; Rani K
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):837-9. PubMed ID: 1562559
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
3. Circulating immune profile in patients with pre-cancer and cancer of the cervix: a cross sectional study among Indian women.
Gupta MM; Jain R; Parashari A; Singh V; Sharma S
Bull Cancer; 1993 Oct; 80(10):852-6. PubMed ID: 8204922
[TBL] [Abstract][Full Text] [Related]
4. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
5. A novel role of metalloproteinase in cancer-mediated immunosuppression.
Sheu BC; Hsu SM; Ho HN; Lien HC; Huang SC; Lin RH
Cancer Res; 2001 Jan; 61(1):237-42. PubMed ID: 11196168
[TBL] [Abstract][Full Text] [Related]
6. Role of zinc and alpha2 macroglobulin on thymic endocrine activity and on peripheral immune efficiency (natural killer activity and interleukin 2) in cervical carcinoma.
Mocchegiani E; Ciavattini A; Santarelli L; Tibaldi A; Muzzioli M; Bonazzi P; Giacconi R; Fabris N; Garzetti GG
Br J Cancer; 1999 Jan; 79(2):244-50. PubMed ID: 9888464
[TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immunity in patients with invasive carcinoma of the cervix.
Park TK; Kim SN
Yonsei Med J; 1989; 30(2):164-72. PubMed ID: 2800566
[TBL] [Abstract][Full Text] [Related]
8. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors.
Hakim AA
Cancer; 1988 Feb; 61(4):689-701. PubMed ID: 2962732
[TBL] [Abstract][Full Text] [Related]
11. Immunological disorder against the Epstein-Barr virus infection and prognosis in patients with cervical carcinoma.
Kitano Y; Fujisaki S; Nakamura N; Miyazaki K; Katsuki T; Okamura H
Gynecol Oncol; 1995 May; 57(2):150-7. PubMed ID: 7537239
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 production in lymphocyte cultures: a rapid test for cancer-associated immunodeficiency in malignant cervical neoplasia.
Radhakrishna Pillai M; Balaram P; Bindu S; Hareendran NK; Padmanabhan TK; Nair MK
Cancer Lett; 1989 Oct; 47(3):205-10. PubMed ID: 2699725
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection from nephrotoxicity.
Smith AY; Citterio F; Welsh M; Kerman RH; Kahan BD
Transplant Proc; 1989 Feb; 21(1 Pt 2):1462-4. PubMed ID: 2652467
[No Abstract] [Full Text] [Related]
14. Relationship of IL-2, IL-2R (CD25+), soluble IL-2R and IL-4 with disease activity in SLE patients.
Cuadrado MJ; Marubayashi M; Ortega C; Fernandez-Arcas N; Garcia-Cozar F; Pena J; Sanchez-Guijo P; Santamaria M
Lupus; 1993 Aug; 2(4):257-60. PubMed ID: 8268974
[TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclosporin on interleukin 2-related T-lymphocyte parameters in IDDM patients.
Chatenoud L; Feutren G; Nelson DL; Boitard C; Bach JF
Diabetes; 1989 Feb; 38(2):249-56. PubMed ID: 2644144
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistological study on HLA class II antigen expression and lymphocyte infiltration in cancer tissues of the uterine cervix].
Nakamura M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Mar; 44(3):349-56. PubMed ID: 1607758
[TBL] [Abstract][Full Text] [Related]
18. The growth factor IL-2 activates p21ras proteins in normal human T lymphocytes.
Graves JD; Downward J; Izquierdo-Pastor M; Rayter S; Warne PH; Cantrell DA
J Immunol; 1992 Apr; 148(8):2417-22. PubMed ID: 1532814
[TBL] [Abstract][Full Text] [Related]
19. Signaling defects and functional impairment in T-cells from cervical cancer patients.
Cheriyan VT; Krishna SM; Kumar A; Jayaprakash PG; Balaram P
Cancer Biother Radiopharm; 2009 Dec; 24(6):667-73. PubMed ID: 20025546
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome.
Aboulghar MA; Mansour RT; Serour GI; El Helw BA; Shaarawy M
Eur J Obstet Gynecol Reprod Biol; 1999 Nov; 87(1):81-5. PubMed ID: 10579621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
